IFLR1000

Search results

Narrow your search

Result types
Article type
Jurisdiction
Practice area
Industry sector
Bar admission

Showing 1851 - 1860 of 2972 for "Al Tamimi & Company" with applied filters

News & Analysis

Kuwait: Legal notice update Ministerial Resolution No.26 of 2021

01 February 2021 by Dr. Ahmad Alshorbagy, Legal Consultant – International Division, Zenab Khajah, Associate – International Division, Al-Hamad Legal Group - Kuwait

To facilitate litigation procedures, the Ministry of Justice has issued a new Ministerial Resolution No. 26 of 2021 concerning the conditions and controls of legal notices (the “Resolution”).
News & Analysis

Luxembourg listed companies: ESEF requirements delayed by one year

27 January 2021 by Arendt & Medernach

Please be informed that the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) has decided to postpone the application of the requirements of the European Single Electronic Format (ESEF) to annual financial reports by one year.
News & Analysis

Bahamas: 15 FAQs on the digital assets and registered exchanges (‘dare’) act, 2020

25 January 2021 by Aliya Allen, Sean McWeeney Jr, Graham Thompson

In the first issue of GT’s News & Insights Volume 3, GrahamThompson Partner Aliya Allen and Associate Sean McWeeney Jr. review 15 FAQs on the Digital Assets and Registered Exchanges (‘DARE’) Act, 2020.
News & Analysis

Higgs & Johnson Announces New Co-Managing Partner

21 January 2021 by Higgs & Johnson

Today, Higgs & Johnson is pleased to announce that Mr. Sterling Harvey Cooke has been appointed the new Co-Managing Partner of the Firm, effective 1 January 2021. He will serve alongside current Co-Managing Partner, Oscar N. Johnson, Jr.
News & Analysis

Zambia announces tax and business reforms to rebuild economy

18 January 2021 by Bowmans, Bwalya Chilufya-Musonda, Partner, and Joshua Mwamulima, Senior Associate, Bowmans Zambia (B&M Legal Practitioners)

Business and tax reforms are on the cards in Zambia as the Government seeks to rebuild the economy and stimulate growth in the wake of the COVID-19 pandemic.

News & Analysis

Olaniwun Ajayi – NIGERIA LAW FIRM OF THE YEAR

07 December 2020 by IFLR Correspondent

Olaniwun Ajayi won IFLR’s inaugural Nigeria Law Firm of the Year award for its work on many of the market’s most innovative cross-border transactions of 2019-2020.
News & Analysis

Helmy, Hamza & Partners, Baker McKenzie Cairo advises National Service Projects Organization on its strategic collaboration with Grifols

02 December 2020 by Helmy Hamza & Partners

Cairo, Egypt, December 2, 2020 - Helmy, Hamza & Partners, Baker McKenzie Cairo office, has represented the National Service Projects Organization (NSPO), on a strategic joint venture with Grifols, one of the world's leading producers of plasma-derived medicines. The collaboration is a significant opportunity to develop the Egyptian plasma-derivatives market and promote its self-sufficiency.
News & Analysis

GSK Stockmann promotes fourteen lawyers from their own ranks

16 November 2020 by GSK

On the occasion of their partner meeting on 13th/14th November, GSK Stockmann appointed three new Equity Partners, nine Local Partners and two Counsel from their own ranks. In doing so, the law firm continues to pursue its (inter)national growth targets even during Corona’s challenging times, focussing above all on the development and encouragement of its own up-and-coming legal talents.
News & Analysis

UBS Switzerland AG, Credit Suisse (Switzerland) Ltd. and Zürcher Kantonalbank arrange refinancing of Arbonia

16 November 2020 by Niederer Kraft Frey

Niederer Kraft Frey advised UBS Switzerland AG, acting as coordinator and arranger, and Credit Suisse (Switzerland) Ltd
News & Analysis

Homburger advised Molecular Partners in connection with a collaboration with Novartis to develop DARPin® therapies designed for potential use against COVID-19

29 October 2020 by Homburger

On October 28, 2020, Molecular Partners AG (SIX: MOLN) (Molecular Partners), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin
Load more